^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
CLL/SLL with del(17p)/TP53 mutation: First-line therapy...Preferred regimens…Acalabrutinib ± obinutuzumab
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Chronic Lymphocytic Leukemia)
New
Excerpt:
acalabrutinib (Calquence) is accepted for restricted use within NHSScotland....as monotherapy for the treatment of adult patients with previously untreated CLL who have a 17p deletion or TP53 mutation and in whom chemoimmunotherapy is unsuitable.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Excerpt:
...- Relapsed/Refractory CLL or treatment naïve CLL patients with 17p deletion, TP53 mutation, or NOTCH1 mutation...
Trial ID: